Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
17.75 GBX | +29.09% | +22.41% | +51.06% |
May. 03 | Angle shares up on assay development deal with AstraZeneca | AN |
May. 03 | Angle shares up on assay development deal with AstraZenaca | AN |
Sales 2023 * | 2.08M 2.61M | Sales 2024 * | 7.61M 9.55M | Capitalization | 46.23M 58M |
---|---|---|---|---|---|
Net income 2023 * | -19M -23.84M | Net income 2024 * | -14M -17.56M | EV / Sales 2023 * | 16.2 x |
Net cash position 2023 * | 12.56M 15.76M | Net cash position 2024 * | 1.6M 2.01M | EV / Sales 2024 * | 5.86 x |
P/E ratio 2023 * |
-2.36
x | P/E ratio 2024 * |
-3.13
x | Employees | - |
Yield 2023 * |
-
| Yield 2024 * |
-
| Free-Float | 89.26% |
Latest transcript on ANGLE plc
1 day | +29.09% | ||
1 week | +22.41% | ||
Current month | +29.09% | ||
1 month | +44.90% | ||
3 months | +4.41% | ||
6 months | +42.00% | ||
Current year | +51.06% |
Managers | Title | Age | Since |
---|---|---|---|
Andrew Newland
FOU | Founder | 63 | 94-03-31 |
Ian Griffiths
DFI | Director of Finance/CFO | - | 94-12-31 |
Karen Miller
CTO | Chief Tech/Sci/R&D Officer | - | 23-06-04 |
Members of the board | Title | Age | Since |
---|---|---|---|
Ian Griffiths
DFI | Director of Finance/CFO | - | 94-12-31 |
Andrew Newland
FOU | Founder | 63 | 94-03-31 |
Brian Howlett
BRD | Director/Board Member | 80 | 13-01-06 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-03 | 17.75 | +29.09% | 7,404,983 |
24-05-02 | 13.75 | -1.79% | 201,963 |
24-05-01 | 14 | +1.82% | 659,855 |
24-04-30 | 13.75 | -1.79% | 492,464 |
24-04-29 | 14 | -3.45% | 975,246 |
Delayed Quote London S.E., May 03, 2024 at 11:35 am EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+51.06% | 58.03M | |
-42.33% | 2.84B | |
+17.00% | 1.85B | |
-0.51% | 1.66B | |
+27.15% | 1.26B | |
-13.90% | 989M | |
-21.76% | 896M | |
-2.72% | 757M | |
-23.95% | 637M | |
+6.84% | 500M |
- Stock Market
- Equities
- AGL Stock